Platelet and leukocyte counts and leukocytotoxic and platelet antibodies were studied in 32 patients with autoimmune hemolytic anemia (AHA). Leukopenia was present in 59.4%, thrombocytopenia in 59.4% and leukothrombo-cytopenia in 40.5% of the cases. Specific antibodies for granulocytes were found in 81.3%, platelet antibodies in 90.6%. The AHA, leukopenia and thrombocytopenia generally presented a dissociated evolution and a different response to immunosuppressive treatment. The leukopenia of 2 and the thrombocytopenia of 6 patients appeared at variable time intervals after the AHA or the detection of leukocyte and platelet antibodies. Thrombocytopenic purpura was present in 6 patients, and in 2 of these since infancy. AHA may thus be a complex autoimmune syndrome that may involve leukocytes and platelets as well as erythrocytes, with synthesis of autoantibodies specific for different blood cells.

Keywords:
Autoantibodies, Erythrocyte antibodies, Granulocytopenia, Hemolytic anemia, Leukocyte antibodies, Platelet antibodies, Thrombocytopenia
This content is only available via PDF.
© 1976 S. Karger AG, Basel
1976
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.